Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorio Reig Jofre Buyback Yield % Related Terms
Laboratorio Reig Jofre Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Laboratorio Reig Jofre's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:RJF vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorio Reig Jofre's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorio Reig Jofre Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorio Reig Jofre's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Laboratorio Reig Jofre's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorio Reig Jofre (XMAD:RJF) has a Buyback Yield % of 0.00 as of Jul. 18, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Laboratorio Reig Jofre and its competitors. According to the industry distribution chart, Laboratorio Reig Jofre ranks #999999 out of 291 companies in the Drug Manufacturers industry.
Is Laboratorio Reig Jofre's Buyback Yield % too high?
Laboratorio Reig Jofre's current Buyback Yield % is 0.00. Based on the distribution chart, Laboratorio Reig Jofre ranks #999999 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Laboratorio Reig Jofre has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorio Reig Jofre's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorio Reig Jofre ranks #999999 out of 291 companies for Buyback Yield %. This places Laboratorio Reig Jofre in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Laboratorio Reig Jofre and its competitors. Laboratorio Reig Jofre's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorio Reig Jofre stock overvalued right now?
Based on GuruFocus' analysis, Laboratorio Reig Jofre (XMAD:RJF) is currently considered Fairly Valued. The stock's GF Value™ is €2.72, compared to a current price of €2.62 — trading 3.7% below its estimated fair value. The current Buyback Yield % is 0.00. Laboratorio Reig Jofre's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Laboratorio Reig Jofre (XMAD:RJF), the current Buyback Yield % is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorio Reig Jofre (XMAD:RJF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorio Reig Jofre stock appears to be undervalued.
The current stock price of €2.62 is trading 3.7% below its estimated GF Value™ of €2.72.
GuruFocus considers Laboratorio Reig Jofre to be Fairly Valued.
Key valuation signals for XMAD:RJF:
Buyback Yield %: 0.00
GF Value™: €2.72 vs. price of €2.62 (3.7% below fair value)
No single metric tells the full story. See the XMAD:RJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.
80GF Score
Get the complete analysis for XMAD:RJF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:RJF has been successfully added to your 
